1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Mar 2024
Admin
News Article

Novartis Biopharm Manufacturing Starts in Singapore

Novartis Expands Biopharmaceutical Manufacturing Facility in Singapore

Overview

Novartis has commenced the expansion of its biopharmaceutical manufacturing plant in Singapore, announcing a significant investment of US$256 million. This expansion aims to integrate digital and automation solutions to enhance manufacturing productivity, operational efficiency, and workforce skills. The focus of the expanded site will be on producing therapeutic antibody drugs to provide groundbreaking treatments to patients worldwide.

Emphasis on Innovation

Mr. Heng Swee Keat, Deputy Prime Minister and Coordinating Minister for Economic Policies, emphasized the importance of continuous innovation in manufacturing for the biopharma sector.
He highlighted Singapore's well-established biomedical ecosystem, expressing confidence in collaboration with global partners like Novartis to deliver innovative biologics products.

Novartis on Biopharmaceutical Supply Chain

Steffen Lang, President of Operations at Novartis, underscored the growing significance of biotherapeutics in addressing patient needs.
He mentioned the substantial growth in Novartis' early-stage biologics portfolio and emphasized the timely nature of the new facility in Singapore, slated to be operational by early 2026.
Lang highlighted its role in strengthening the biopharmaceutical manufacturing and supply chain across Asia, as well as enhancing local capabilities and talent in Singapore.

Generating Jobs

The endeavor is expected to create 100 high-skilled job openings, contributing to the expansion of the local life science sector.
Novartis is committed to investing in talent development, providing training for existing employees to excel in the digitalized and automated environment of the expanded facility.

The Guest-of-Honor

The groundbreaking event was graced by Deputy Prime Minister Heng Swee Keat as the Guest-of-Honor, along with Frank Grütter, Swiss Ambassador to Singapore, and Ms. Cindy Koh, Executive Vice President of EDB, among others.

Novartis Efforts

Novartis has maintained a strong partnership with Singapore since 1986, with over US$1 billion invested to uplift the nation's pharmaceutical manufacturing capabilities.
The Novartis Singapore manufacturing site, established since 2002, has been pivotal in the company's biopharmaceutical production efforts, supported by the Singapore government.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!